STOCK TITAN

CORCEPT THERAPEUTICS (CORT) SEC Filings, Aug 3-14, 2026

CORT NASDAQ

Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.

The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.

Rhea-AI Summary

Corcept Therapeutics Inc’s Chief Business Officer, Gary Charles Robb, reported several bona fide gift transactions in the company’s common stock on August 12, 2026. He made a gift disposition of 11,530 shares, leaving 13,551 shares held directly, including unvested restricted stock awards. He also reported gifts of 3,000 shares to each of two custodial accounts for his children, which are reported as indirect holdings. Separately, an additional 49,716 shares are held indirectly through the Gary Charles Robb TTE Robb Revocable Trust.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
insider
-
Rhea-AI Summary

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of common stock of Corcept Therapeutics Inc. They state beneficial ownership of 5,261,628 shares of common stock, representing 4.90% of the class. The filing indicates sole voting and sole dispositive power over all 5,261,628 shares, with no shared voting or dispositive power. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and proceeds from the sale of these securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.58%
Tags
ownership
-
Rhea-AI Summary

Corcept Therapeutics executive Sean Maduck exercised options for 1,031 shares of common stock at $8.27 per share and sold the same 1,031 shares at a weighted average price of $114.5182 on August 10, 2026. Following the option exercise, he held 95,650 stock options directly, and also holds various indirect positions through trusts and LLCs. The sale was executed under a Rule 10b5-1 trading plan adopted on December 8, 2025. His direct holdings include unvested restricted stock awards that vest one year after their respective grant dates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
insider
Rhea-AI Summary

Corcept Therapeutics Chief Development Officer William Guyer reported an options exercise and related sales. On 2026-08-10, he exercised a stock option for 16,300 shares of common stock at an exercise price of $21.65 per share, leaving 110,000 options outstanding under that award, which is fully exercisable. The same day, he acquired 16,300 common shares through the exercise and sold 11,530 shares at a weighted average of $113.1772 (actual prices from $112.80 to $113.75) and 4,770 shares at a weighted average of $114.0371 (actual prices from $113.98 to $114.24). The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2024, and his reported holdings include unvested restricted stock awards scheduled to vest on their one-year anniversaries if service conditions are met.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
insider
-
Rhea-AI Summary

Corcept Therapeutics Chief Development Officer William Guyer exercised stock options to acquire 3,700 shares of common stock at $21.65 per share on August 4, 2026 and sold 3,700 shares at a weighted average price of $113.1248 per share under a Rule 10b5-1 plan adopted on November 27, 2024.

The options exercised were fully exercisable, and 126,300 option shares remained directly held after the transaction. The reported common stock position includes unvested restricted stock awards that each vest 100% on the one-year anniversary of their respective grant dates, subject to specified conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
insider
-
Rhea-AI Summary

On 2026-08-03, Corcept Therapeutics executive Sean Maduck exercised stock options for 20,305 shares of common stock at $8.27 per share and sold the same number of shares at a weighted average price of $114.7045 (range $114.49–$115.00), pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. He continues to hold 96,681 stock options and additional common stock, including unvested restricted stock awards and indirect holdings through trusts and LLCs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
insider
Rhea-AI Summary

Corcept Therapeutics chief accounting & technology officer Joseph Douglas Lyon reported a sale of 1,540 shares of common stock on August 3, 2026, at $114.16 per share in an open-market or private transaction. After this trade, he holds 5,495 shares, including 200, 178, 398 and 537 shares underlying unvested restricted stock awards granted on September 2, 2025, December 1, 2025, March 2, 2026 and June 1, 2026, which will fully vest on the one-year anniversaries of their grant dates if required conditions are satisfied.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
insider
-
Rhea-AI Summary

CORT has filed to permit the sale of 20,000 shares of common stock on NASDAQ, expected to be effected for cash on August 4, 2026, with an indicated aggregate value of $2,256,000.00.

The transaction is tied to a stock option exercise by William Guyer. Over the prior three months, Guyer reported three separate sales of 20,000 shares each, on May 5, 2026, June 2, 2026, and July 7, 2026, with respective sale values of $1,035,501.00, $1,410,964.00, and $1,861,491.00.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.66%
Tags
other
-
Rhea-AI Summary

Corcept Therapeutics Chief Financial Officer Mokari Atabak exercised stock options covering 80,000 shares of common stock at an exercise price of $23.06 per share on July 30, 2026, then sold 80,000 shares in multiple open-market or private transactions the same day.

The sales occurred at prices ranging from $105.305 to $120.84 per share. The option was fully exercisable and expires on February 13, 2033, with 95,833 options from this grant remaining. All reported sales were made under a Rule 10b5-1 trading plan adopted on December 12, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.66%
Tags
insider
Rhea-AI Summary

Corcept Therapeutics Inc. officer Joseph Douglas Lyon reported 1,540 common shares for sale, with an aggregate market value of $175,806 and an approximate sale date of August 3, 2026. The notice lists Stifel Nicolaus & Company Inc. as broker. Lyon acquired 749 shares through an option exercise on June 2, 2025, and 791 shares through an option exercise on June 3, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
other

FAQ

How many CORCEPT THERAPEUTICS (CORT) SEC filings are available on StockTitan?

StockTitan tracks 201 SEC filings for CORCEPT THERAPEUTICS (CORT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for CORCEPT THERAPEUTICS (CORT)?

The most recent SEC filing for CORCEPT THERAPEUTICS (CORT) was filed on November 13, 2026.